Setia Putra Tarigan
Universitas Sumatera Utara

Published : 2 Documents Claim Missing Document
Claim Missing Document

Found 2 Documents

Proportion of Mutation of Epidermal Growth Factor Receptor (EGFR) Genes from Tissue Biopsy and Liquid Biopsy ctDNA in Lung Adenocarcinoma Hendra Taufik; Noni Novisari Soeroso; Setia Putra Tarigan; Erna Mutiara
Jurnal Respirologi Indonesia Vol 40, No 3 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.118


Backgrounds: In recent years, circulating tumor DNA (ctDNA) has emerged as a specific and sensitive blood-based biomarker to detect EGFR mutations. This study aims to determine the diagnostic accuracy of ctDNA in detecting EGFR gene mutations in adenocarcinoma lung cancer. Methods: This study was a cross-sectional study with the subjects were adenocarcinoma lung cancer patients from histopathology or cytology examination and examined EGFR mutations from plasma tissue biopsy and ctDNA specimens from April 2018 to February 2019 in several hospitals in the Medan City. Results: There were 100 data have been collected, with male were 71 subjects and female were 29 subjects. Found 20 mutations, single mutations of tissue biopsy were 19 cases, del exon 19 were 12 cases, mutation in exon 21 (L858R) were 6 cases, mutation exon 21 (L861Q) was 1 case, del exon 19 and 21 (L861Q double mutations) was 1 case. From plasma ctDNA examination EGFR mutations were found 15 cases, del exon 19 were 12 cases and del exon 21 (L858R) were 3 cases. Conclusions: The highest proportion of EGFR mutations by sex were women from tissue biopsy or ctDNA, the most often frequency of EGFR mutations from tissue biopsy and ctDNA in single mutations and exons19. (J Respir Indo. 2020; 40(3): 150-5)
The Association of Acquired Resistance EGFR Exon 20 T790M Mutation and Treatment Response in Lung Adenocarcinoma Patients Receiving EGFR-TKI: Relationship between Acquired Resistance T790M Mutation and RECIST 1.1 Muhammad Harbi Praditya; Noni Novisari Soeroso; Setia Putra Tarigan; Taufik Ashar
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.32


Background: Lung adenocarcinoma patients receiving EGFR-TKI may develop acquired resistance within 7-16 months of treatment initiation, which is characterized by the presence of exon 20 T790M mutations in treatment response patients and can be assessed objectively by CECT and then evaluated by RECIST 1.1. The purpose of this study is to look into the association between acquired resistance EGFR Exon 20 T790M mutation and treatment response in lung adenocarcinoma patients receiving EGFR-TKI. Method: This research is an analytic study with a retrospective cohort design carried out at the Oncology Polyclinic at Haji Adam Malik Hospital from October 2020 to January 2021 in all patients with adenocarcinoma lung cancer who were treated with EGFR-TKI for more than 6 months. After that, an evaluation was carried out based on RECIST 1.1 and then examined for EGFR mutations from liquid biopsy specimens in the form of circulating tumor plasma DNA (ct-DNA) with the droplet digital Polymerase Chain Reaction (ddPCR) method to detect EGFR exon 20 T790M mutations as a marker of acquired resistance. Results: It was found that the majority of subjects were female (64.5%), aged 20-69 years (58%), and non-smokers (67.7%). The most common EGFR mutation was exon 19 deletion (58.1%). The incidence of acquired resistance was found in 10 subjects (32.3%). The distribution of RECIST 1.1 results on positive acquired resistance includes progressive diseases of 35.2%; stable disease of 11.1%; partial response of 33.4%; and 100% complete response. Negative acquired resistance includes 64.8% progressive disease, 88.9% stable disease, 66.6% partial response, and 0% complete response (P=0.93). Conclusion: There is no significant association between the incidence of acquired resistance mutations EGFR exon 20 T790M and treatment response in patients with lung adenocarcinoma who received EGFR-TKI therapy.